Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 in uncontrolled asthma
NCT03226392Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing QAW039 Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in Pre-dose Forced Expiratory Volume in 1 second at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03226392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226392.